Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. CGTX
CGTX logo

CGTX

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

CGTX News

Cognition Advances Zervimesine Development for DLB Psychosis Treatment

Mar 02 2026Newsfilter

Cognition Extends Expanded Access Program for DLB

Feb 05 2026Newsfilter

Post-Market Winners: A Calm Trading Day Highlighted by a Notable Biotech Rise

Dec 17 2025NASDAQ.COM

Biotech and Healthcare Stocks Top After-Hours Gainers: ICU, CGTX, MESO, VRCA, AHCO

Nov 26 2025NASDAQ.COM

HC Wainwright & Co. Affirms Buy Rating for Cognition Therapeutics, Keeps $3 Price Target Intact

Nov 19 2025Benzinga

Cognition Therapeutics Finishes Participant Enrollment for Phase 2 Trial of Zervimesine (CT1812) in Early Alzheimer's Disease

Nov 13 2025Newsfilter

CGTX, RVPH, SHOT, SONN, AKTX Surge in After-Hours Trading Following Clinical Developments and Fed Rate Cut Expectations

Sep 18 2025NASDAQ.COM

Biotech Stocks Surge After Hours Due to Trial Advancements, Funding Developments, and Anticipated Milestones

Sep 17 2025NASDAQ.COM

Monday's Underperforming Sectors: General Contractors & Builders, Pharmaceuticals

Sep 15 2025NASDAQ.COM

Cognition Therapeutics Achieves 75% Enrollment Goal for Zervimesine (CT1812) Study in Early Alzheimer's Disease

Sep 03 2025Newsfilter

The 5 Best-Performing Stocks in the Nasdaq Composite for August 2025

Sep 03 2025NASDAQ.COM

Snowflake Shares Surge 14%; Check Out 20 Stocks Making Moves in Premarket Trading

Aug 28 2025Benzinga

Cognition Therapeutics Initiates $30 Million Stock Offering

Aug 28 2025SeekingAlpha

Cognition Therapeutics Meets Nasdaq Compliance for $1.00 Bid Price Requirement

Aug 26 2025SeekingAlpha

Why Sapiens International Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket

Aug 13 2025Benzinga

Cognition Therapeutics Surges 30% Pre-Market After FDA Backs Phase 3 Trial Design For Alzheimer's Drug

Aug 13 2025Benzinga